STOCK TITAN
  1. Home
  2. Sec-filings
  3. MAZE
  4. [Form 4] Maze Therapeutics, Inc. Insider Trading Activity

Maze Therapeutics (MAZE) director stock option moves and share sales

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Maze Therapeutics director Catherine A. Sohn reported a series of stock option exercises and related common share sales. On January 6, 2026, she exercised 2,493 stock options at an exercise price of $10.42 per share and sold 2,493 common shares at a weighted average price of $38.616 per share, leaving no common shares directly owned.

On January 7, 2026, she exercised additional options for 20,744, 2,895, and 3,281 common shares at an exercise price of $10.42 per share and then sold 26,920 common shares at a weighted average price of $39.1079 per share, again ending with 0 common shares directly held. Following these transactions, she continues to hold stock options, including 3,211, 316, and 5,805 derivative securities with expiration dates between 2031 and 2034.

Positive

  • None.

Negative

  • None.
Insider Sohn Catherine A.
Role Director
Sold 29,413 shs ($1.15M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 20,744 $0.00 --
Exercise Stock Option (Right to Buy) 2,895 $0.00 --
Exercise Stock Option (Right to Buy) 3,281 $0.00 --
Exercise Common Stock 20,744 $10.42 $216K
Exercise Common Stock 2,895 $10.42 $30K
Exercise Common Stock 3,281 $10.42 $34K
Sale Common Stock 26,920 $39.1079 $1.05M
Exercise Stock Option (Right to Buy) 2,493 $0.00 --
Exercise Common Stock 2,493 $10.42 $26K
Sale Common Stock 2,493 $38.616 $96K
Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 20,744 shares (Direct)
Footnotes (1)
  1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive. The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024. The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sohn Catherine A.
(Last) (First) (Middle)
C/O MAZE THERAPEUTICS, INC.
171 OYSTER POINT BOULEVARD, SUITE 300
(Street)
SOUTH SAN FRANCISCO CA 94080
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/06/2026 M 2,493 A $10.42 2,493 D
Common Stock 01/06/2026 S 2,493 D $38.616(1) 0 D
Common Stock 01/07/2026 M 20,744 A $10.42 20,744 D
Common Stock 01/07/2026 M 2,895 A $10.42 23,639 D
Common Stock 01/07/2026 M 3,281 A $10.42 26,920 D
Common Stock 01/07/2026 S 26,920 D $39.1079(2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $10.42 01/06/2026 M 2,493 (3) 03/08/2033 Common Stock 2,493 $0 3,211 D
Stock Option (Right to Buy) $10.42 01/07/2026 M 20,744 (4) 02/01/2031 Common Stock 20,744 $0 0 D
Stock Option (Right to Buy) $10.42 01/07/2026 M 2,895 (3) 03/08/2033 Common Stock 2,895 $0 316 D
Stock Option (Right to Buy) $10.42 01/07/2026 M 3,281 (5) 12/08/2034 Common Stock 3,281 $0 5,805 D
Explanation of Responses:
1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive.
3. The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
4. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.
5. The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
/s/ Courtney Phillips, as attorney-in-fact 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

Who is the insider in this Maze Therapeutics (MAZE) Form 4 filing?

The filing reports transactions by Catherine A. Sohn, who is identified as a director of Maze Therapeutics, Inc. and the sole reporting person on the form.

What stock option exercises did Catherine A. Sohn report for Maze Therapeutics (MAZE)?

She exercised Maze Therapeutics stock options with an exercise price of $10.42 per share, including 2,493 options on January 6, 2026 and 20,744, 2,895, and 3,281 options on January 7, 2026, each for an equivalent number of common shares.

What Maze Therapeutics common stock sales were disclosed in this Form 4?

On January 6, 2026, she sold 2,493 common shares at a weighted average price of $38.616 per share. On January 7, 2026, she sold 26,920 common shares at a weighted average price of $39.1079 per share, with both weighted averages based on multiple trades within disclosed price ranges.

How many Maze Therapeutics common shares did the director hold after these transactions?

After the reported sales on both January 6, 2026 and January 7, 2026, the amount of Maze Therapeutics common stock beneficially owned directly by the reporting person is shown as 0 shares following each sale.

What Maze Therapeutics stock options does the director continue to hold after the Form 4 transactions?

Following the exercises, the form shows continuing direct ownership of 3,211 stock options with a March 8, 2033 expiration, 316 stock options with a March 8, 2033 expiration, and 5,805 stock options with a December 8, 2034 expiration, each exercisable for Maze Therapeutics common stock at $10.42 per share.

What do the footnotes say about the Maze Therapeutics share sale prices in this Form 4?

The footnotes state that the reported sale prices are weighted average prices. For the January 6, 2026 sale, trades occurred between $38.61 and $38.6225 per share. For the January 7, 2026 sale, trades occurred between $39.04 and $39.85 per share.

How do the Maze Therapeutics stock option awards vest for the director?

Footnotes explain that certain options vest as to 1/36th of the total award monthly, starting on April 1, 2023 or January 1, 2025, with continued service required on each vesting date. Another option grant is described as fully vested as of February 2, 2024.